NYSE:INO
Inovio Pharmaceuticals Stock News
$11.88
-0.220 (-1.82%)
At Close: May 06, 2024
Inovio Pharmaceuticals, Inc. (INO) CEO Dr. Joseph Kim on Q4 2021 Results - Earnings Call Transcript
02:19am, Wednesday, 02'nd Mar 2022 Seeking AlphaInovio Pharmaceuticals (INO) Reports Q4 Loss, Tops Revenue Estimates
11:05pm, Tuesday, 01'st Mar 2022 Zacks Investment Research
Inovio (INO) delivered earnings and revenue surprises of -51.52% and 301.44%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Inovio Pharmaceuticals results miss on the bottom line; shares down 9% (INO)
09:42pm, Tuesday, 01'st Mar 2022 Seeking Alpha
Inovio Pharmaceuticals'' (INO) Q4 2021 results missed on the bottom line as its net loss significantly widened.
Inovio Pharmaceuticals, Inc. (INO) CEO Dr. Joseph Kim on Q4 2021 Results - Earnings Call Transcript
09:19pm, Tuesday, 01'st Mar 2022
Inovio Pharmaceuticals, Inc. (INO) CEO Dr. Joseph Kim on Q4 2021 Results - Earnings Call Transcript
Inovio Pharmaceuticals GAAP EPS of -$1.45 misses by $0.19, revenue of $1.77M beats by $0.31M
09:11pm, Tuesday, 01'st Mar 2022 Seeking Alpha
Inovio Pharmaceuticals press release (INO): FY GAAP EPS of -$1.45 misses by $0.19.Revenue of $1.77M (-76.1% Y/Y) beats by $0.31M.Shares -5.56%.As of December 31, 2021, cash and…
2 Money-Burning Biotech Stocks to Avoid
01:45pm, Tuesday, 01'st Mar 2022 The Motley Fool
These companies have taken a beating, and there's no relief on the horizon.
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution
12:51pm, Tuesday, 01'st Mar 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Editas Gains On Resolution Of CRISPR Gene Editing Patent Case
Editas Medicine, Inc. (NASDAQ: EDIT) sai
Can Inovio Pharmaceuticals Q4 results bring earnings surprise?
05:20pm, Monday, 28'th Feb 2022 Seeking Alpha
Inovio Pharmaceuticals (NASDAQ:INO) is scheduled to announce Q4 earnings results on Tuesday, March 1st, after market close.The consensus EPS Estimate is -$0.32 (-128.6% Y/Y) and…
Stock Runner: Inovio Pharmaceuticals, Inc. (NASDAQ:INO), Alcoa Corporation (NYSE:AA)
09:23am, Monday, 28'th Feb 2022 Stock Equity
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) with the stream of -0.31% also noticed, India Alcoa Corporation (NYSE:AA) encountered a rapid change of 6.21% in the last hour of trading session. Inovio Pharmaceuticals, … The post Stock Runner: Inovio Pharmaceuticals, Inc. (NASDAQ:INO), Alcoa Corporation (NYSE:AA) appeared first on Stocks Equity .
Thinking About Buying Stock In AMC Entertainment, Romeo Power Or Inovio Pharmaceuticals?
01:26pm, Thursday, 24'th Feb 2022 Benzinga
Analysts and brokerage firms often use ratings when they issue stock recommendations to stock traders. Analysts arrive at stock ratings by researching public financial statements, communicating with executives and customers and following industry trends. Here are the latest analyst rating updates for AMC Entertainment Holdings Inc (NYSE: AMC ), Romeo Power Inc (NYSE: RMO ) and Inovio Pharmaceuticals Inc (NASDAQ: INO ): The latest price target for AMC was by Wedbush on Nov. 4. The analyst firm set a price target … Full story available on Benzinga.com
This Trend Is the Biggest Risk to Biotech Investors Right Now
04:45pm, Monday, 21'st Feb 2022 The Motley Fool
Wall Street seems to have a grudge against the entire sector at the moment.
Stocks Volume Buzz: Inovio Pharmaceuticals, Inc. (NASDAQ:INO), Teva Pharmaceutical Industries Limited (NYSE:TEVA)
03:28am, Monday, 21'st Feb 2022 Stock Equity
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) with the stream of -1.85% also noticed, India Teva Pharmaceutical Industries Limited (NYSE:TEVA) encountered a rapid change of -2.04% in the last hour of Fridays trading The post Stocks Volume Buzz: Inovio Pharmaceuticals, Inc. (NASDAQ:INO), Teva Pharmaceutical Industries Limited (NYSE:TEVA) appeared first on Stocks Equity .
Alkermes (ALKS) Q4 Earnings and Revenues Beat Estimates
01:55pm, Wednesday, 16'th Feb 2022 Zacks Investment Research
Alkermes (ALKS) delivered earnings and revenue surprises of 76.92% and 1.44%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Molina Healthcare (MOH) Q4 Earnings Beat on Higher Premiums
05:05pm, Thursday, 10'th Feb 2022 Zacks Investment Research
Molina Healthcare (MOH) expects its 2022 business to witness reduced impacts from COVID. Strong Medicare and Medicaid performance is set to buoy results.
Humana (HUM) Q4 Earnings Beat Estimates on Membership Growth
05:43pm, Wednesday, 02'nd Feb 2022 Zacks Investment Research
Humana (HUM) is taking multiple initiatives like cost savings and others to generate $1 billion additional value to fund the Medicare Advantage business and boost Healthcare Services capabilities.